This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahnke, K. Articles by Enk, A. H. Search for Related Content PubMed PubMed Citation Articles by Mahnke, K. Articles by Enk, A. H.

Targeting of Antigens to Activated Dendritic Cells In vivo Cures Metastatic Melanoma in Mice

¹ Department of Dermatology, University of Heidelberg, Heidelberg, Germany and ² Department of Dermatology, University of Mainz, Mainz, Germany

Requests for reprints: Karsten Mahnke, Department of Dermatology, University of Heidelberg, Vosstrasse 3, 69115 Heidelberg, Germany. Phone: 49-6221-568170; Fax: 49-6221-561617; E-mail: karsten.mahnke{at}med.uni-heidelberg.de.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Anti ()-DEC-205 antibodies target to the DEC-205 receptor that mediates antigen presentation to T cells by dendritic cells. To exploit these properties for immunization purposes, we conjugated the melanoma antigen tyrosinase-related protein (TRP)-2 to DEC-205 antibodies and immunized mice with these conjugates together with dendritic cell–activating oligonucleotides (CpG). Upon injection of the melanoma cell line B16, DEC-TRP immunized mice were protected against tumor growth. Even more important for clinical applications, we were able to substantially slow the growth of implanted B16 cells by injection of DEC-TRP2 conjugates into tumor bearing hosts. Approximately 70% of the animals were cured from existing tumors by treatment with DEC conjugates carrying two different melanoma antigens (TRP-2 and gp100). This protection was due to induction of melanoma-specific CD4 and CD8 responses. Thus, these data show that targeting of dendritic cells in situ by the means of antibody-antigen conjugates may be a novel way to induce long-lasting antitumor immunity.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Dendritic cells have been characterized by their exceptional T-lymphocyte stimulatory capacity that is owed to high expression of MHC molecules as well as to abundant expression of T-cell costimulatory molecules.

To exploit these immunostimulatory features of dendritic cells for immunization purposes, studies have been carried out that generate dendritic cells in vitro and load them with known peptides derived from tumor antigens or whole lysate of tumors, respectively. Thereafter, these tumor antigen–loaded dendritic cells were injected into tumor-bearing hosts where the injected dendritic cells eventually home into lymphoid organs and prime an antitumor response (1–3).

Despite some promising clinical trials, these experiments require extensive laboratory work and during in vitro culture, dendritic cells are either fed with known tumor peptides or lysate of whole tumors (4). During this culture, dendritic cells also take up all sorts of in vitro medium ingredients; therefore, the effective number of MHC-tumor antigen complexes expressed by the dendritic cells is difficult to estimate.

Moreover, antigens endocytosed via fluid-phase uptake are degraded to a large extend by immature dendritic cells instead of being loaded onto MHC molecules and only after terminal differentiation MHC-peptide complexes are generated in sizable numbers (5, 6). In vivo, dendritic cells take up antigens by the means of antigen receptors. One example is the DEC-205 receptor (CD205), which guides antigens into deeper endocytic vesicles containing MHC class II molecules. As a consequence of this unique intracellular targeting, antigens endocytosed by the DEC-205 receptor stimulate respective T cells up to 500-fold better than antigens taken up by pinocytosis or by other receptors (7). We could also show that injected anti-DEC-205 antibodies (DEC) target to dendritic cells situated in the lymph nodes (8, 9). Henceforth, loading dendritic cells with tumor antigens via the DEC-205 receptor may result in effective production of MHC-tumor antigen complexes, which eventually lead to induction of protective antitumor immunity (10).

Therefore, we coupled the melanoma antigens tyrosinase-related protein-2 (TRP-2) and gp-100 to antibodies specific for the DEC-205 receptor (DEC) and injected these DEC-tumor antigen conjugates into mice. We show that anti-DEC conjugates load exclusively lymph node dendritic cells, leading to induction of an antitumor response, where up to 70% of the tumor bearing mice rejected the B16 melanomas after DEC-TRP treatment. Thus, these data show that targeting of protein derived tumor vaccines to maturing dendritic cells in vivo greatly enhances antitumor activity and may provide a tool for future cancer therapies.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Construction of recombinant proteins and coupling with antibodies. cDNA of mTRP2 (amino acid, aa 30-518) and enhanced green fluorescent protein (EGFP) were cloned into EcoRI sites of the vector pET43b (Novagen, Schwalbach, Germany). After cloning was confirmed by sequencing, vectors were transformed into Rosetta-gamiDE3 (Novagen) and proteins were isolated with Ni-NTA agarose columns (Qiagen, Hilden, Germany). Purified recombinant proteins were dialyzed against PBS overnight and coupled to anti-DEC-205 antibodies using the cross-linker Sulfo-SMCC (Pierce, Bonn, Germany).

Flow cytometric analysis. For the activation of dendritic cells, the following oligonucleotides were used: 5'-TCCATGACGTTCCTGACGTT-3' (ARK Sigma, Deisenhofen, Germany). Mice were injected with PBS, 10 µg, 50 µg, and 100 µg CpG, respectively, and sacrificed 24 hours later and lymph node cell suspensions were prepared. Thereafter, CD11c⁺ cells were prepared using MACS beads (Miltenyi, Bergisch Gladbach, Germany) according to standard protocols.

For detection of CD80, CD86, and MHC II, respective FITC labeled antibodies (all Becton Dickinson, Heidelberg, Germany) were used at 1:100 dilution and analysis was carried out using a FACScan (Becton Dickinson). For detection of antibodies in the serum of immunized mice, sera were collected and 1 x 10⁶ B16 cells were suspended in 400 µL PBS, 1 mmol/L EDTA, 2% (v/v) FCS and incubated with the anti-sera at 1:100 dilution at 4°C for 30 minutes. Thereafter, FITC-labeled rat anti-mouse antibodies (Dianova, Hamburg, Germany) were added, and following two washes, cell-bound antibodies were analyzed by fluorescence-activated cell sorting (FACS).

ELISA and ELISPOT. ELISA was carried out to detect antibodies specific for mTRP2; 96-well plates (Nunc, Wiesbaden, Germany) were coated overnight with recombinant mTRP2 protein (50 µL per well) in coating buffer [30 mmol/L Na₂CO₃, 70 mmol/L NaHCO₃ (pH 9.6)]. After three washes [2% bovine serum albumin (BSA), 0.01% Thimerosal, 0.5% Tween 20 in PBS], antisera were added and incubated at 4°C for 2 hours. After several washes, 100 µL per well rat anti-mouse peroxidase conjugates (Dianova) at a 1:3000 dilution were added and incubated at 4°C for 1 hour. Thereafter, 100 µL per well ABTS + 1N H₂O₂ (Sigma) were added for 10 minutes at room temperature and plates were evaluated at 405 nm with ELISA plate reader (Bio-Rad, Muenchen, Germany). For the detection of cytokines, T cells from immunized mice were isolated with anti-CD4 beads on MACS columns according to the manufacturer's protocol (Miltenyi). CD4⁺ T cells were then restimulated with dendritic cell pulsed with recombinant protein mTRP2 in vitro for 3 days, and supernatants were collected and used for ELISA to detect IFN-, interleukin 2 (IL-2), IL-4, IL-10, tumor necrosis factor- (TNF-), production with standard ELISA kits (R&D Systems, Wiesbaden, Germany).

For detection of mTRP2-specific CD8⁺ T cells, ELISPOTs were carried out as follows: Mice injected with conjugates or PBS were sacrificed and single spleen cell suspensions were prepared with standard protocols and cultivated in ELISPOT plates (Nunc) that had been precoated with 50 µL per well rat-anti-mouse-IFN antibodies in PBS (10 µg/mL; PharMingen, Heidelberg, Germany) overnight at 4°C.

For stimulation, mTRP2 peptide (aa 180-188) or the known CD8⁺ T cell epitope (SVYDFFVWL) was added (1 µg/mL). ß-Galactosidase (ß-gal) peptide and RPMI alone served as controls. Plates were incubated at 37°C for 24 hours at 5% CO₂ and developed with 100 µL biotinylated rat-anti-mouse IFN (5 µg/mL) in assay buffer (0.5% BSA, 0.05% Tween 20 in PBS). Thereafter, 100 µL per well streptavidin-POD were added and incubated at room temperature for 30 minutes. Color was developed by addition of 50 µL per well of 3,3'-diaminobenzidine developer (peroxidase substrate kit; Vector, Birmingham, CA), and the number of mTRP2 peptide–specific CD8⁺ T cells was evaluated by counting.

Vaccination and tumor challenge experiments. All animal protocols were approved under the guidelines of the animal protection act. For protective experiments, female B6 mice (6-8 weeks old) were injected s.c. with 10 µg DEC-205 conjugates in PBS plus 50 µg CpG twice at an interval of 1 week. One week after the second injection, each mouse was challenged for tumor growth by i.v. injection of 4 x 10⁵ B16 cells in 100 µL PBS; after 2 weeks, mice were sacrificed and lung metastasis were countered. As control, 100 µL PBS + 50 µg CpG were injected.

For therapeutic experiments, tumor growth was induced by s.c. injection of 5 x 10³ B16 cells in the right flank. After 1 week when the tumor growth was first seen (diameter, 1 mm), 10 µg DEC-205 conjugates in PBS + 50 µg CpG per mouse were injected. The injection was repeated after 1 week and tumor growth was measured twice to thrice a week with a caliper ruler. In some experiments, CD4^–/– and CD8^–/– B6 mice were used.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
DEC-TRP-2 conjugates target to dendritic cells in vitro and in vivo. To make DEC targeting applicable for many different tumor settings, we successfully set out to produce, purify, and couple known tumor antigens TRP-2 and gp-100 to DEC antibodies (Fig. 1A).

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Figure 1. Targeting of DEC-TRP conjugates to dendritic cells in vitro and in vivo. A, DEC antibodies (lane 1) were coupled to recombinant TRP2 protein. This coupling resulted in aggregates of 150 kDa in size (lane 2). As a comparison, purified TRP2 is shown in lane 3. B, bone marrow–derived dendritic cells were incubated with DEC-EGFP for 2 hours and stained with Texas red conjugated anti-MHC class II antibodies. EGFP fluorescence (left); MHC staining (right). Examples of colabeling (arrows). C, DEC-EGFP conjugates and controls as indicated were injected into mice and draining lymph nodes were removed 4, 8, and 12 hours thereafter and CD11c+ cells were prepared. EGFP fluorescence was measured by FACS after gating onto the CD11c+ cells. D, CpG at doses as indicated were injected s.c. into the hint flanks of mice, and lymph node cells were prepared and stained for CD11c in PE and CD86 in FITC 24 hours later.

Next we investigated whether s.c. injection of the DEC-EGFP also results in effective in vivo targeting to dendritic cells in regional lymph nodes. For this, DEC-EGFP and respective controls were injected into mice and draining lymph nodes were removed as indicated. Figure 1C shows that 4 hours after injection 19% and 8 hours later 32% of the dendritic cells in the draining lymph nodes accumulated DEC-EGFP protein. This is a rapid accumulation compared with cellular migration. Because it takes Langerhans cells >6 hours to migrate from skin to regional lymph nodes, we conclude that DEC-EGFP conjugates target to antigen presentation compartments in dendritic cells in vitro and in vivo. However, after injection of uncoupled protein some fluorescence slightly above background levels was detectable, resulting in only 6% to 8% of all dendritic cells being loaded (background level was 4%).

Dendritic cells are activated by CpG. Presentation of antigen(s) by immature dendritic cells leads to tolerance, whereas concomitant activation of the dendritic cells by CD40 antibodies leads to induction of immunity. However, CD40 antibodies are not approved for clinical trials in humans yet; therefore, we reasoned to inject CpG as dendritic cell activators, because this approach is currently under investigation in human trials (11).

To test the optimal concentration in our tumor model, mice were injected with different doses of CpGs and dendritic cells were purified 24 hours later. Thereafter, cells were stained for the maturation markers CD86 and CD80. Figure 1D shows, that injection of CpG increased dendritic cell maturation dose dependently as indicated by enhanced CD86 expression. We found that 50 µg CpG was optimal, as further increase of the CpG concentration did not result in enhanced CD86 expression. Therefore, in subsequent experiments, DEC-TRP2 conjugates were injected together with 50 µg of CpGs (DEC-TRP2_CpG).

Induction of antibody responses against tyrosinase-related protein. To test whether injection DEC-TRP2_CpG induces TRP-specific immune responses, we injected mice with DEC-TRP2_CpG and respective controls as indicated, and 14 days later, the serum was tested for TRP-2-specific antibodies. Figure 2A shows that mice injected with DEC-TRP2_CpG conjugates developed a more vigorous antibody response against the TRP-2 protein compared with controls. Moreover, no antibodies against TRP-2 were observed after immunization of mice with isotype conjugates.

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 2. Induction of anti-TRP2 antibodies after DEC-TRPCpG injection. Mice were immunized as indicated and sera were obtained 2 weeks after last immunization. A, thereafter, anti-sera were tested in ELISA plates, which had been coated with TRP-2 protein and respective controls. TRP-specific antibodies bound to the plate were then detected using horseradish peroxidase–coupled secondary reagents and colorimetric substrates. Columns, means of the absorbance (O.D.) of quadruplicates. B, B16 melanoma cells were incubated with antisera obtained from immunized mice as indicated and surface bound antibodies were detected using FITC labeled secondary reagents. Thereafter, samples were analyzed by FACS.

Induction of TRP-2-specific CD4⁺ T cells. To further test whether cellular responses (i.e., TRP-2-specific CD4⁺ T cells) were induced by DEC-TRP2_CpG immunizations, we isolated CD4⁺ T cells from immunized mice and restimulated with mTRP2-pulsed bone marrow–derived dendritic cells. Here (Fig. 3A), T cells obtained from DEC-TRP2_CpG and DEC-TRP2 plus anti-CD40 antibody injected mice showed vigorous proliferation upon restimulation in vitro. In contrast, when mice were immunized with unconjugated TRP2_CpG, isotype controls, or DEC-TRP2 without activation, no T-cell proliferation could be recorded.

View larger version (20K): [in this window] [in a new window] [Download PPT slide]   Figure 3. Induction of antitumor T-cell responses. A, mice were immunized with conjugates and respective controls as indicated on the x-axis. After 1 week, CD4+ T cells from lymph nodes were prepared and restimulated in 96-well plates with either TRP or ß-gal protein, respectively. T-cell proliferation was determined by [3H]-thymidine uptake. Columns, means of triplicates; bars, ±SD. *, P < 0.05, significant difference to isotype-treated controls. B, mice were immunized with DEC-TRP conjugate or TRP protein as indicated. Thereafter, T cells were prepared from lymph nodes and restimulated in vitro. Supernatants were recovered and tested for cytokines as indicated using ELISA. Columns, means of triplicates; bars, ±SD. C, mice were immunized with conjugates and respective controls as indicated on the x-axis. Thereafter, CD4-depleted spleen cells were prepared and cultured in anti-IFN coated ELISPOT plates. Cells were pulsed with known CD8-specific peptides as indicated and plates were developed and spots were counted 48 hours later. Columns, means of triplicates; bars, ±SD. *, P < 0.05, significant difference to "no-peptide" controls. As a control for tumor protection (as published), mice were immunized with recombinant adenovirus-encoding human TRP-2 (Ad-hTRP).

Induction of CD8⁺ T cells. Because previous results have shown that fractions of antigens endocytosed by DEC-205 are also presented in context of MHC class I molecules (8), we next checked for induction of TRP-2-specific CD8⁺ T cells. Therefore, we immunized mice with DEC-TRP_CpG conjugates and respective controls, isolated spleen cells 7 days after the second immunization, and restimulated the CD4-depleted T cells with the known MHC class I–specific TRP-2 peptide in ELISPOT plates. The quantity of spots as depicted in Fig. 3C shows that substantial numbers of IFN producing T cells were induced after immunization with DEC-TRP_CpG. In contrast, after injection of TRP_CPG or Isotype-TRP_CpG, no spots above background levels could be recorded. To further verify the antigen specificity, we stimulated spleen cells with the matched MHC class I peptide derived from the unrelated protein ß-gal. In these controls, we could not detect any spots, indicating that the induced IFN producing CD8⁺ T cells were specific for the TRP-2 peptide. Injection of recombinant adenovirus encoding for human TRP-2 served as a positive control (12). In summary, these data show that immunization of mice with DEC-TRP2_CpG conjugates leads to induction of antibodies as well as to induction of TRP-2-specific CD4⁺ and CD8⁺ T cells.

Induction of protective antitumor immunity in mice. To investigate the effects of DEC-TRP2_CpG immunization in an in vivo tumor model, we immunized mice with the different DEC-conjugates and respective controls twice in weekly intervals and challenged for tumor growth by i.v. injection of 4 x 10⁵ viable B16 melanoma cells. After 2 weeks, mice were sacrificed, lungs were removed, and lung metastases were counted. In these experiments, we could show (Fig. 4) that 80% of the mice immunized with DEC-TRP2_CpG conjugates were protected from tumor growth. In contrast, after immunization with TRP_CpG antigen alone or a mixture of DEC antibodies and TRP_CpG respectively, no protection was apparent. In these instances, up to 100% of the mice had metastases developing in their lungs. Coupling TRP-2 to irrelevant antibodies, which may facilitate uptake by Fc receptors expressed by antigen presenting cells, was not sufficient to induce tumor protection, because RatIgG-TRP-2 conjugates as well as MHC II TRP-2 conjugates failed to induce protection.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Figure 4. Vaccination with DEC-TRP conjugates prevents tumor growth. A, groups of 5 C57/Bl6 mice were immunized twice with conjugates as indicated, and 1 week later, tumor growth was challenged by i.v. injection of 4 x 105 B16 melanoma cells. Fourteen days later, animals were sacrificed and lung metastasis were counted. Columns, % tumor-free mice of four independent experiments; bars, ±SD. As a control for tumor protection (as published), mice were immunized with recombinant adenovirus encoding-human TRP-2 (Ad-hTRP). B, groups of either CD8 knockout (KO CD8–/–) mice or CD4 KO (CD4–/–) mice were immunized and challenged as in (A). Wild-type mice (WT) served as controls. Columns, % tumor-free mice as in (A).

Treatment of developing melanoma by injection of DEC-TRP_CpG. In clinical settings, a therapeutic approach (i.e., the treatment of tumor-bearing individuals) is desirable. Therefore, we investigated the effect of DEC-TRP2_CpG injection on already existing melanomas. We injected B16 melanoma cells first and waited until palpable tumors (1-mm diameter) have developed. Thereafter, mice were treated by injection of 10 µg per mouse DEC-TRP2_CpG. All mice received two injections of the conjugates in a 4-day interval and the growth of s.c. melanomas was measured by a caliper ruler. Here (Fig. 5), we could show that injection of DEC-TRP2_CpG substantially slowed melanoma growth and protected up to 50% of the mice from tumor growth. In contrast, injection of uncoupled TRP-2 protein or CpG alone as well as mixtures of TRP-2 and CpG did not affect tumor growth and nearly 100% of all melanoma-bearing mice died.

View larger version (20K): [in this window] [in a new window] [Download PPT slide]   Figure 5. Treatment of developing melanomas by injection of DEC-TRP conjugates. A, B16 melanoma cells were injected into the shaved abdomen of mice. After developing melanomas were visible (1 mm2), mice were treated as indicated and volumes of the melanomas were determined. Points, mean tumor volumes of groups of five mice in a typical experiment. B, in parallel, the number of tumor free mice was determined. Columns, means of 3 independent experiments; bars, ±SD.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Tumor antigen–pulsed dendritic cells have been used in several clinical trials to induce tumor immunity with variable success (3, 4).Therefore, we reasoned to load dendritic cell directly in vivo with relevant tumor antigens by the means of antibody targeting.

For this aim, several prerequisites are mandatory. First, the antigen has to be targeted specifically to activated dendritic cells that are able to induce strong immunity in vivo. Second, the antigen has to be endocytosed by the dendritic cells to generate significant numbers of MHC-peptide complexes that eventually are presented to T cells in vivo.

Both criteria are fulfilled by DEC-205 antibodies and here we show that DEC-tumor antigen conjugates target to dendritic cells located in the lymph nodes. Upon injection, the DEC coupled antigens were efficiently loaded onto dendritic cells in vivo and protective antitumor immunity was induced when conjugates were applied together with dendritic cell–activating stimuli. Even more interesting, we were also able to cure mice from B16 melanomas by the DEC-tumor antigen treatment.

For antigen targeting, the DEC-205 molecule is an ideal candidate, because this molecule mediates effective generation of MHC-peptide complexes and is almost exclusively expressed by dendritic cells (7, 13, 14). Some successful targeting of dendritic cells using antibodies against surface receptors with broader specificity (i.e., anti-FcR or anti-chemokine receptors) has been observed previously, but the effect on immunity was rather weak (15, 16). Presumably, the FcR conjugates were taken up by a variety of different lymphocytes, such as macrophages, B cells, and spleen dendritic cells, thus "diluting" the targeting effect (17, 18). The DEC-205 conjugates in contrast, target specifically to dendritic cell in vivo without being "caught" and eliminated by binding to macrophages and/or B cells, respectively. Because dendritic cells are by far the most effective inducers of T-cell responses, dendritic cell–specific targeting contributes to the effective immunization against melanoma.

TRP-2 coupled to DEC was present in lymph node dendritic cells within the first hour after injection (8). Soon thereafter, DEC-coupled antigens could be traced beyond the regional lymph nodes. Because it takes skin-derived dendritic cells (Langerhans cells) >6 hours to migrate from the skin to regional lymphatics and migration beyond lymphatic organs of Langerhans cells does not occur, we conclude that the DEC-antigen conjugates themselves reach the lymph nodes and were not transported from the skin via immigrating Langerhans cells. This broad loading of dendritic cell in virtually all lymph nodes is in contrast to results observed with in vitro generated, antigen-loaded dendritic cells. After injection of these dendritic cells, only 3% to 5% reach lymphoid organs and their migration is restricted to the regional lymph nodes only (19). Therefore, the systemic distribution of DEC-antigen conjugates enables loading of virtually all lymph node dendritic cells in the body and provides a basis for the induction of a more powerful immune response compared with conventional immunization strategies.

The successive receptor internalization and intracellular sorting of the antibody-antigen conjugates further determines the generation of sizable numbers of MHC-peptide complexes that eventually are presented to T cells. In this regard, the novel intracellular targeting pathway of the DEC-205 receptor is crucial. Previous results indicate that DEC-205 targets directly into MHC class II compartments where novel MHC-peptide complexes are generated to stimulate CD4⁺ T cells (7). CD8 responses were also induced, although results obtained with CD8 knockout mice indicated only a minor role in tumor protection. However, these results were expected because other TRP-2-derived tumor models suggest that CD4⁺ T cells are crucial for providing "help" for the development of tumor-specific cytotoxic CD8⁺ T cells (20). Thus, depletion of CD4⁺ T cells prevents the mounting of an effective immune response because B cells, CTLs, and other cellular components are only partially activated.

Other receptors such as the FcR mainly feed into proteolytic pathways resulting in degradation and diminished MHC-peptide complex generation (18). In contrast, DEC-guided antigens displayed a long half-life (8) indicating that the intracellular compartments served by DEC are only mildly proteolytic.

Furthermore, certain subtypes of receptors (e.g., FcRII) possess signaling capacity leading to inhibition of immune responses via ITIM motives (21). Therefore, the intracellular "en route" targeting of the antibody-antigen conjugates guided by DEC-205 avoids the loss of putative antigenic peptides caused by protein degradation in lysosomal compartments and MHC-peptide complexes are produced with a high efficiency.

Generally, the targeting of antigens to dendritic cells does not activate immune responses per se, because several investigations have shown that concomitant activation of dendritic cell is crucial for induction of immune responses (22, 23). In this regard, the application of immune stimulatory substances such as CpG may have a 2-fold effect on the development of tumor immunity in our B16 model. First, as already mentioned, CpG ensures proper activation of the dendritic cells; second, it may activate the endothelium of tumor blood vessels. This may be important because Garbi et al. (24) have shown that proper activation of endothelium is crucial for the extravasation of tumor-specific T cells from the blood into cancerous tissues.

In contrast to "immunization" experiments, "cure" experiments are much more demanding, because the immune system has to fight cancer cells that are already proliferating. Despite this "head start" for the tumor cells, we had reasonable success by "curing" up to 70% of melanoma bearing mice by coupling two known tumor antigens (i.e., TRP-2 and gp100 together) to DEC antibodies (25). In principle, the generation of fusion proteins that harbor even more then two melanoma epitopes is possible and even more interesting; one can speculate that also simultaneous expression of dendritic cell activating epitopes may be possible. That would obliviate the need to coinject dendritic cell activating stimuli and one can speculate that the coupling of such "multiepitope plus activation proteins" to DEC antibodies may further improve the tumor therapy with DEC-205 mediated in vivo targeting.

In summary, our results show that targeting of tumor antigens to dendritic cell in vivo may provide us with a tool to immunize against and to treat diseases. The use of DEC targeting may not be restricted to tumor antigens, because for other infectious diseases or virally infections, protein antigens are characterized. Therefore, coupling of these antigens to DEC may improve vaccination efficiency. Because the DEC-205 molecule is equally expressed by human dendritic cells (26) and shares a high (up to 90%) amino acid sequence homology with murine DEC-205, it is conceivable that human DEC-205 has similar properties as antigen receptor and therefore may be a useful target for developing vaccination strategies in human trials.

	Acknowledgments

 
Grant support: Deutsche Forschungsgemeinschaft grants Ma 1924/2-1 and SFB 405 and the Tumor-Center Heidelberg/Mannheim.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	Footnotes

 
Note: K. Mahnke and Y. Qian contributed equally to this work.

Received 3/21/05. Revised 5/ 2/05. Accepted 5/10/05.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243–51.[CrossRef][Medline]
2. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451–8.[Abstract/Free Full Text]
3. Dhodapkar M, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173–80.[Medline]
4. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.[CrossRef][Medline]
5. Turley SJ, Inaba K, Garrett WS, et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science 2000;288:522–7.[Abstract/Free Full Text]
6. Pierre P, Turley SJ, Gatti E, et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997;388:787–92.[CrossRef][Medline]
7. Mahnke K, Guo M, Lee S, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000;3:673–84.
8. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8(+) T cell tolerance. J Exp Med 2002;196:1627–38.[Abstract/Free Full Text]
9. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769–79.[Abstract/Free Full Text]
10. Bonifaz L, Bonnyay P, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004;199:815–24.[Abstract/Free Full Text]
11. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000;30:3591–7.[CrossRef][Medline]
12. Steitz J, Brueck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism. Gene Ther 2001;8:1255–63.[CrossRef][Medline]
13. Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995;375:151–5.[CrossRef][Medline]
14. Witmer-Pack MD, Swiggard WJ, Mirza A, Inaba K. Steinman RM. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell Immunol 1995;163:157–62.[CrossRef][Medline]
15. Schjetne KW, Gundersen HT, Iversen JG, Thompson KM, Bogen B. Antibody-mediated delivery of antigen to chemokine receptors on antigen-presenting cells results in enhanced CD4+ T cell responses. Eur J Immunol 2003;3:3101–8.
16. Squire C, Studer E, Lees A, Finkelman F, Conrad H. Antigen presentation is enhanced by targeting antigen to the FceRII by antigen-anti-FcR-conjugates. J Immunol 1998;152:4388–95.
17. Serre K, Machy P, Grivel JC, et al. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J Immunol 1998;161:6059–67.[Abstract/Free Full Text]
18. Mellman IS, Plutner H, Steinman RM, Unkeless JC. Cohn ZA Internalization and degradation of macrophage Fc receptors during receptor-mediated phagocytosis. J Cell Biol 1983;96:887–95.[Abstract/Free Full Text]
19. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12–7.[Abstract/Free Full Text]
20. Steitz J, Brueck J, Gambotto A, Knop J, Tueting T. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther 2002;9:208–13.[CrossRef][Medline]
21. Billadeau DD, Leibson PJ. ITAMs versus ITIMs: striking a balance during cell regulation. J Clin Invest 2002;109:161–8.[CrossRef][Medline]
22. Inaba K, Turley S, Iyoda T, et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000;191:927–36.[Abstract/Free Full Text]
23. De Smedt T, Pajak B, Muraille E, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996;184:1413–24.[Abstract/Free Full Text]
24. Garbi N, Arnold B, Gordon S, Hammerling GJ, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 2004;172:5861–9.[Abstract/Free Full Text]
25. Mendiratta SK, Thai G, Eslahi NK, et al. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res 2001;61:859–63.[Abstract/Free Full Text]
26. Guo M, Gong S, Maric S, et al. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol 2000;61:729–38.[CrossRef][Medline]

This article has been cited by other articles:

				T. S. Johnson, K. Mahnke, V. Storn, K. Schonfeld, S. Ring, D. M. Nettelbeck, H. J. Haisma, F. Le Gall, R. E. Kontermann, and A. H. Enk Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule Clin. Cancer Res., December 15, 2008; 14(24): 8169 - 8177. [Abstract] [Full Text] [PDF]

				M. Flobakk, I. B. Rasmussen, E. Lunde, T. Frigstad, G. Berntzen, T. E. Michaelsen, B. Bogen, and I. Sandlie Processing of an Antigenic Sequence from IgG Constant Domains for Presentation by MHC Class II J. Immunol., November 15, 2008; 181(10): 7062 - 7072. [Abstract] [Full Text] [PDF]

				X.-D. Tang, Y. Wan, L. Chen, T. Chen, S.-T. Yu, Z. Xiong, D.-C. Fang, G.-P. Liang, and S.-M. Yang H-2Kb-Restricted CTL Epitopes from Mouse Heparanase Elicit an Antitumor Immune Response In vivo Cancer Res., March 1, 2008; 68(5): 1529 - 1537. [Abstract] [Full Text] [PDF]

				E. Tagliani, P. Guermonprez, J. Sepulveda, M. Lopez-Bravo, C. Ardavin, S. Amigorena, F. Benvenuti, and O. R. Burrone Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8{alpha}+ Dendritic Cells J. Immunol., March 1, 2008; 180(5): 3201 - 3209. [Abstract] [Full Text] [PDF]

				O. Adotevi, B. Vingert, L. Freyburger, P. Shrikant, Y.-C. Lone, F. Quintin-Colonna, N. Haicheur, M. Amessou, A. Herbelin, P. Langlade-Demoyen, et al. B Subunit of Shiga Toxin-Based Vaccines Synergize with {alpha}-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity J. Immunol., September 1, 2007; 179(5): 3371 - 3379. [Abstract] [Full Text] [PDF]

				R. S. Kornbluth and G. W. Stone Immunostimulatory combinations: designing the next generation of vaccine adjuvants J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102. [Abstract] [Full Text] [PDF]

				D. Bruder, A. M. Westendorf, W. Hansen, S. Prettin, A. D. Gruber, Y. Qian, H. von Boehmer, K. Mahnke, and J. Buer On the Edge of Autoimmunity: T-Cell Stimulation by Steady-State Dendritic Cells Prevents Autoimmune Diabetes Diabetes, December 1, 2005; 54(12): 3395 - 3401. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mahnke, K. Articles by Enk, A. H. Search for Related Content PubMed PubMed Citation Articles by Mahnke, K. Articles by Enk, A. H.